Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
After Mirati opened the week with a multibillion-dollar buyout, we take a look at Bristol Myers Squibb’s budding rivalry with Amgen, Pfizer’s planned cost cuts, a surprise CRL for Alnylam, a busy stream of clinical readouts and much, much more. Don’t miss our roundup of the key takeaways from our #EuroBio23 summit in London.
BMS buys Mirati for $4.8B
Bristol Myers Squibb revealed on Sunday that it’s signed a $4.8 billion deal to buy Mirati Therapeutics and its cancer drug Krazati, the culmination of what appears to be a hectic few days of negotiations following reports that Sanofi is in M&A…
Click here to view original post
